References in periodicals archive ?
MRF's DDAG is tasked with assessing and prioritizing the organization's myelin repair therapeutic targets and advising the MRF scientific team on the development of industry-competitive data packages.
The interaction between our scientific team and the DDAG members was extraordinary.
Said DDAG member and former VP of research from Amgen Mike Gresser, "The traditional gap between university-based science and commercial drug development has often meant that too much good science has not advanced toward potential patient treatments.